Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Solid State Boost at Onyx

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Company unveils huge increase in demand for solid-state chemistry services.

Onyx Scientific has unveiled a huge increase in demand for its solid-state chemistry services versus last year.

The contract research and manufacturing organization has reported a 45% uplift in solid formulation related revenues, which is being driven by early stage drug development projects.

The company’s close alliance with Molecular Profiles, announced last year, has also led to more work as a result of increasing activity in the biotechnology and early stage clinical sector.

Denise Bowser, commercial director at Onyx Scientific, said: “Over the past few years, we have proudly become a real specialist in solid-state chemistry focused on providing detailed investigation to cut lead times for clients and ensure processes are scalable.

“As many drugs are formulated in solid dosage form, the need to understand, control and characterize the individual forms of a substance, in particular the polymorphic form, is vital. This is why we feel we have seen such an increased demand.”

In 2013, the company has worked with pharmaceutical and biotech clients across the globe assisting with integrated chemistry, process development and custom synthesis projects.

With MHRA and FDA facilities in the UK and India, Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.

Its UK-based labs deal with complex chemistry to deliver early stage programs and is then able to scale-up, tech transfer and increase project efficiency using its commercial manufacturing sites in India.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CRO to Expand GMP Capability
Company will install a new Class 100,000 suite at its facility in North East England.
Thursday, April 02, 2015
Onyx to Expand Capabilities
Reach alliance broadens specialist purification, separation services.
Tuesday, August 07, 2012
Onyx Strengthens Commercial Team
Appointment of Brian Jolly as director of European business development.
Monday, May 28, 2012
API Firm Posts Impressive Growth
UK-based Onyx Scientific has grown 27% as the business continues to build its pharmaceutical and biotech client-based in Europe, Japan and the US.
Thursday, June 02, 2011
Onyx Scientific Clinches Cancer Research UK Contract
Cancer Research UK has selected Onyx Scientific to develop the chemistry and perform the GMP synthesis of the API for use in a Phase 1 clinical trial.
Thursday, May 12, 2011
Scientific News
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!